JP2013540771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540771A5 JP2013540771A5 JP2013533235A JP2013533235A JP2013540771A5 JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5 JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- terminal
- pharmaceutical composition
- terminally modified
- modified insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 8
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 8
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 8
- 108090001061 Insulin Proteins 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 102000004877 Insulin Human genes 0.000 claims 6
- 229940125396 insulin Drugs 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 238000011191 terminal modification Methods 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003495 polar organic solvent Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- -1 thiocarbamoyl Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-ZYCCASTOSA-N 8a-l-threonine-10a-l-isoleucine-insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 NOESYZHRGYRDHS-ZYCCASTOSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 108010066090 neutral insulin Proteins 0.000 claims 1
- 125000003431 oxalo group Chemical group 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 0 *N(*)CC(I)=O Chemical compound *N(*)CC(I)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10187706 | 2010-10-15 | ||
| EP10187706.6 | 2010-10-15 | ||
| US39409010P | 2010-10-18 | 2010-10-18 | |
| US61/394,090 | 2010-10-18 | ||
| PCT/EP2011/068019 WO2012049307A2 (en) | 2010-10-15 | 2011-10-14 | Novel n-terminally modified insulin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013540771A JP2013540771A (ja) | 2013-11-07 |
| JP2013540771A5 true JP2013540771A5 (enExample) | 2014-11-20 |
Family
ID=43638785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013533235A Withdrawn JP2013540771A (ja) | 2010-10-15 | 2011-10-14 | 新規n末端修飾インスリン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140315797A1 (enExample) |
| EP (1) | EP2627670A2 (enExample) |
| JP (1) | JP2013540771A (enExample) |
| CN (1) | CN103154024A (enExample) |
| WO (1) | WO2012049307A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| KR20150002777A (ko) | 2012-04-11 | 2015-01-07 | 노보 노르디스크 에이/에스 | 인슐린 제제 |
| SG10201809457YA (en) * | 2014-11-21 | 2018-11-29 | Merck Sharp & Dohme | Insulin receptor partial agonists |
| WO2017032795A1 (en) * | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| CA2996455A1 (en) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| EP3341402A1 (en) * | 2015-08-25 | 2018-07-04 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| EP3458032A4 (en) | 2016-05-16 | 2019-12-25 | The Board of Regents of The University of Texas System | CATIONIC SULFONAMIDE AMINOLIPIDS AND AMPHIPHILE ZWITTERIONIC AMINOLIPIDS |
| MA49116A (fr) | 2016-12-16 | 2020-03-25 | Novo Nordisk As | Compositions pharmaceutiques contenant de l'insuline |
| PE20211264A1 (es) | 2017-08-17 | 2021-07-15 | Novo Nordisk As | Analogos de insulina acilados novedosos y usos de estos |
| SG11202106168VA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin analogs having reduced insulin receptor binding affinity |
| BR112021016782A2 (pt) * | 2019-03-29 | 2021-11-30 | Novo Nordisk As | Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica |
| FI4073097T3 (fi) | 2019-12-11 | 2024-08-13 | Novo Nordisk As | Uusia insuliinianalogeja ja niiden käyttötapoja |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0792290T1 (en) * | 1993-09-17 | 2001-12-31 | Novo Nordisk As | Acylated insulin |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| JP5410020B2 (ja) * | 2005-02-02 | 2014-02-05 | ノヴォ ノルディスク アー/エス | インスリン誘導体 |
| EP1888118B1 (en) | 2005-05-25 | 2016-08-17 | Novo Nordisk A/S | Polypeptide formulations stabilized with ethylenediamine |
| EP2404934A1 (en) | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Protease resistant insulin analogues |
| EP2164466A1 (en) * | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| WO2008145721A2 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| KR20100053561A (ko) * | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| CN106317164A (zh) * | 2008-09-12 | 2017-01-11 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| EP2344200A2 (en) | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| EP2370059A1 (en) * | 2008-11-28 | 2011-10-05 | Novo Nordisk A/S | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
| CN102753150A (zh) | 2010-01-12 | 2012-10-24 | 诺沃—诺迪斯克有限公司 | 用于口服给予胰岛素肽的药物组合物 |
-
2011
- 2011-10-14 EP EP11770428.8A patent/EP2627670A2/en not_active Withdrawn
- 2011-10-14 US US13/823,952 patent/US20140315797A1/en not_active Abandoned
- 2011-10-14 CN CN2011800496891A patent/CN103154024A/zh active Pending
- 2011-10-14 WO PCT/EP2011/068019 patent/WO2012049307A2/en not_active Ceased
- 2011-10-14 JP JP2013533235A patent/JP2013540771A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540771A5 (enExample) | ||
| WO2011153493A3 (en) | Biodegradable lipids for the delivery of active agents | |
| WO2008137758A3 (en) | Amino acid lipids and uses thereof | |
| MX2014014902A (es) | Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. | |
| EP4286012A3 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| PE20171095A1 (es) | Acidos grasos novedosos y su uso en la conjugacion con biomoleculas | |
| EP2810661A3 (en) | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids | |
| EP4410317A3 (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| WO2011141705A8 (en) | Novel cationic lipids and methods of use thereof | |
| WO2010147655A3 (en) | Compositions and methods relating to nucleic acid delivery vehicles | |
| EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
| EP4241767A3 (en) | Novel lipids and compositions for the delivery of therapeutics | |
| WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
| WO2012054500A3 (en) | Compositions for drug administration | |
| WO2015048498A3 (en) | Carrier-free biologically-active protein nanostructures | |
| EP3037417A3 (en) | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
| Muthukumarasamyvel et al. | Hierarchical self-assembly of bile-acid-derived dicationic amphiphiles and their toxicity assessment on microbial and mammalian systems | |
| RU2015140996A (ru) | Топическая противомикробная дерматологическая композиция | |
| EA201070484A1 (ru) | Новые конъюгаты нейртурина для фармацевтического применения | |
| EP2928462A4 (en) | METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID | |
| Abioye et al. | Self-assembled food peptides: recent advances and perspectives in food and health applications | |
| WO2009076388A3 (en) | Targeting vector-phospholipid conjugates | |
| HK1203157A1 (en) | Sustained delivery of molecules using peptide surfactants and uses thereof | |
| EP4227685A3 (en) | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus | |
| ZA201404068B (en) | The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents |